DONALD CAREY HARRISON, M.D.
Osteopathic Medicine at Piedmont Ave, Cincinnati, OH

8178123, May 15, 2012

Sep 15, 2006

11/522126

Giovanni M. Pauletti - Loveland OH, US
Donald C. Harrison - Cincinnati OH, US
Kishorkumar J. Desai - Westchester OH, US

Femina Pharma Incorporated - Miami FL

A61F 2/02

424423

A vaginal or buccal delivery of therapeutic agents having a substrate affinity for metabolic cytochrome P-450 enzymes and membrane efflux transporter systems. A method for augmentation of systemic exposure to the therapeutic agents having a substrate affinity for cytochrome P-450 enzymes and membrane efflux transporter systems, by delivering said agents to the systemic circulation through vaginal or buccal mucosa.

2004015, Aug 5, 2004

Oct 31, 2003

10/698794

Giovanni Pauletti - Loveland OH, US
Kishorkumar Desai - Westchester OH, US
Susan Roweton - Raleigh NC, US
Donald Harrison - Cincinnati OH, US
Lynda Sanders - Los Altos CA, US

A61K009/14

424/486000, 424/488000

Polymer foams and films for delivery of therapeutic agents to and through nasal, oral or vaginal mucosa and cornified or non-cornified epithelium of labia and scrotum. Polymer foams or absorbable or non-absorbable films containing a therapeutic agent incorporated therein wherein said agent is released from said foams or films upon placement of said foam or film on the surface epithelium of nasal, oral, or vaginal labia or scrotum. The foam or the film has a controllable rate of gelling, swelling and degradation and is preformed into a device or is applied as a coating to a surface of a more complex drug delivery system.

6053942, Apr 25, 2000

Aug 18, 1998

9/135879

Robert A. Eno - Plymouth MN
Donald C. Harrison - Cincinnati OH
Jerry Griffin - Chicago IL

Heartstent Corporation - St. Paul MN

A61F 206, A61F 204

623 115

A transmyocardial implant includes a hollow rigid conduit having a first portion and a second portion. The first portion is sized to be larger than an initial lumen diameter of a coronary vessel. The first portion is smaller than an enlarged lumen diameter. The second portion is sized to extend from the first portion and through a myocardium into a heart chamber. The implant further includes a stent having a first stent diameter and adapted to be enlarged to an enlarged second stent diameter. In the first stent diameter, the stent is sized to be inserted into the initial lumen diameter. In the second diameter, the stent is sized to dilate the lumen to the enlarged lumen diameter. When the stent is at the second stent diameter, the stent has an internal diameter sized to receive the first portion of the conduit.

6086909, Jul 11, 2000

Feb 12, 1999

9/249963

Donald C. Harrison - Cincinnati OH
James H. Liu - Cincinnati OH
Wolfgang A. Ritschel - Cincinnati OH
Roger A. Stern - Cupertino CA

UMD, Inc. - Cincinnati OH

A61F 606, A61F 1302, A61F 614

424430

Methods, devices, and compositions for treatment of dysmenorrhea comprise an intravaginal drug delivery system containing an appropriate pharmaceutical agent incorporated into a pharmaceutically acceptable carrier whereby the pharmaceutical agent is released into the vagina and absorbed through the vaginal mucosa to provide relief of dysmenorrhea. The drug delivery system can be a tampon device, vaginal ring, pessary, tablet, suppository, vaginal medicated tampon, vaginal sponge, bioadhesive tablet, bioadhesive microparticle, cream, lotion, foam, ointment, paste, solution or gel. The system delivers a higher concentration to the muscle of the uterus, the primary site for the dyskinetic muscle contraction, which is the pathophysiologic cause of dysmenorrhea.

2005016, Jul 28, 2005

Mar 16, 2005

11/082367

Steven Gehling - Oshkosh WI, US
Donald Harrison - Indian Hill OH, US
James Liu - Bratenahl OH, US
Wolfgang Ritschel - Cincinnati OH, US
Roger Stern - Sunnyvale CA, US

A61L015/00

424445000, 424404000

A tampon adapted to deliver a therapeutic agent, the tampon including a tampon body that is manufactured at a first manufacturing facility; and a dosage form coupled to the body, wherein the dosage form includes a formulation including a therapeutic agent, and wherein the dosage form is manufactured at a second manufacturing facility. Also, a method for producing a medicated tampon including manufacturing a tampon body at a first manufacturing facility; manufacturing a dosage form at a second manufacturing facility, wherein the dosage form includes a formulation including a therapeutic agent; and coupling the dosage form to the tampon body.

7341737, Mar 11, 2008

Dec 31, 2002

10/335759

Steven Craig Gehling - Oshkosh WI, US
Donald C. Harrison - Indian Hill OH, US
James H. Liu - Bratenahl OH, US
Wolfgang A. Ritschel - Cincinnati OH, US
Chris Clendening - Cleves OH, US
Giovanni M. Pauletti - Loveland OH, US

Kimberly-Clark Worldwide, Inc. - Neenah WI

A61F 13/02, A61F 9/02, A61F 13/20

424431, 424430, 424433, 424436, 424729, 424732, 424744, 424754, 424757, 424767, 514966, 514967, 604358, 604604

A tampon adapted to deliver a therapeutic agent, the tampon including a tampon body having a distal end; and a dosage form affixed to the distal end of the tampon body, wherein the dosage form includes a formulation including a therapeutic agent, and wherein the dosage form comprises a plurality of layers. Also, a method for manufacturing a medicated tampon adapted to deliver a therapeutic agent, the method including manufacturing a tampon body having a distal end; producing a dosage form having a plurality of layers, wherein the dosage form includes a formulation including a therapeutic agent; and affixing the dosage form to the distal end of the tampon body.